title: Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients.
abstract: Baseline CD4 cell counts and human immunodeficiency virus (HIV)-1 RNA levels have been shown to predict immunologic and virologic responses in HIV-infected patients receiving antiretroviral therapy. In our randomized, double-blind, comparative trial, 653 antiretroviral therapy-naive patients received lopinavir/ritonavir or nelfinavir, plus stavudine and lamivudine, for up to 96 weeks. The risk of loss of virologic response was significantly higher for nelfinavir-treated patients than for lopinavir/ritonavir-treated patients (Cox model hazard ratio, 2.2; 95% confidence interval, 1.7-3.0; P<.001). For nelfinavir-treated patients, but not for lopinavir/ritonavir-treated patients, higher baseline HIV-1 RNA levels and lower baseline CD4 cell counts were associated with a higher risk of loss of virologic response.
authors.affiliation: Abbott Laboratories, Abbott Park, Illinois, USA. martin.king@abbott.com
authors.forename: Martin S
authors.initials: MS
authors.lastname: King
authors.forename: Barry M
authors.initials: BM
authors.lastname: Bernstein
authors.forename: Sharon L
authors.initials: SL
authors.lastname: Walmsley
authors.forename: Renslow
authors.initials: R
authors.lastname: Sherer
authors.forename: Judith
authors.initials: J
authors.lastname: Feinberg
authors.forename: Ian
authors.initials: I
authors.lastname: Sanne
authors.forename: Paul
authors.initials: P
authors.lastname: Cernohous
authors.forename: Julio S G
authors.initials: JS
authors.lastname: Montaner
authors.forename: Scott C
authors.initials: SC
authors.lastname: Brun
authors.forename: Eugene
authors.initials: E
authors.lastname: Sun
mesh_terms: D019380:Anti-HIV Agents / Q000494:pharmacology / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D004311:Double-Blind Method; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D061466:Lopinavir; D008297:Male; D019888:Nelfinavir / Q000494:pharmacology / Q000627:therapeutic use*; D011237:Predictive Value of Tests; D011744:Pyrimidinones / Q000494:pharmacology / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood; D012307:Risk Factors; D019438:Ritonavir / Q000494:pharmacology / Q000627:therapeutic use*; D012727:Sex Characteristics; D018119:Stavudine / Q000627:therapeutic use; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D011744:Pyrimidinones; D012367:RNA, Viral; D061466:Lopinavir; D019259:Lamivudine; D018119:Stavudine; D019888:Nelfinavir; D019438:Ritonavir